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Abstract: Several pharmacological studies indicate that CB1 cannabinoid receptors (CB1Rs) are present in guinea pig 
ileum (GPI) and their activation reduce the acetylcholine (Ach) release. Dependence can be induced and measured in vitro 
by using GPI and the contraction due to opioid withdrawal is caused by acetylcholine release. 
Design of molecules acting on the CB1Rs are widely studied and the large availaibility of CB1Rs agonists and antagonists 
provides powerful tools to determine the role of these receptors in mediating some of physiological and pharmacological 
effects in the myenteric neurones. 
Given the relationship between CB1Rs/Opioid Withdrawal/Ach system, in the present paper we have designed six new 
CB1Rs agonists named A-F and evaluated their role in mediating morphine withdrawal in GPI. Also, a comparative study 
was performed by using the CB1Rs synthetic cannabinoid WIN 55,212-2 and CP 55,940. The results of our experiments 
indicate that both WIN 55,212-2 and CP 55,940 (1x10
-8-5x10
-8-1x10
-7 M) were able to reduce morphine withdrawal in a 
concentration-dependent manner. Very similar results were obtained with the new CB1Rs agonists (A-F) used at same 
concentrations. The results of our experiments indicate that CB1Rs are involved in the control of morphine withdrawal in 
vitro thus confirming an important functional interaction between the cannabinoid and opioid system. 
Keywords: Ach. CB1 receptors, morphine, withdrawal, guinea-pig ileum. 
INTRODUCTION 
  Cannabinoid drugs exert a wide range of biological 
effects and are currently under study for their multiple 
potential therapeutic uses [1-4].  
  Cannabinoids and opioid share several pharmacological 
properties [5-7] and a strong interaction between opioid and 
cannabinoid systems has been reported [8-12]. This 
interaction can be studied by using GPI where cannabinoid 
CB1Rs have been found [13, 14]. The enteric nervous 
system has been considered as a simplified version of the 
central nervous system, considering its complex network-
like organization and the presence of a large number of 
neurotrasmitters and neuromodulators. Isolated preparations, 
GPI, have been widely employed for assessing the acute 
effects of opioid and as a model for studying the interactions 
of opioid with other neuronal systems. 
  Dependence can be induced and measured in vitro by 
using GPI [15-18]. Tissues from untreated animals, after a 
brief exposure to opioids, show a strong naloxone-induced 
contracture [15-18] indicating that the cellular mechanisms 
of dependence may occur very rapidly following occupation 
of receptors and that these mechanisms operate within the 
myenteric plexus.  
  The characteristics of dependence development and the 
precipitation of withdrawal by naloxone in the guinea-pig   
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ileum are very similar to those of acute dependence in 
experimental animals and man [15-18]. 
  It has been demonstrated that Ach plays an important role 
in expression of opioid withdrawal because cholinergic 
agonist exacerbate opioid withdrawal; whereas, muscarinic 
and nicotinic blockers attenuate some aspects of the 
syndrome [19, 20]. Furthermore, a large proportion of the 
contraction due to opioid withdrawal is caused by 
acetylcholine release since it can be blocked by atropine or 
hyoscine [21, 22]. 
  Several pharmacological evidences suggest that CB1Rs 
are present in the GPI and the effects on gastrointestinal 
motility depend on their activation which cause a reduction 
of Ach release [23-27].  
  Design of molecules acting on the CB1Rs are widely 
studied and the large availaibility of CB1Rs agonists and 
antagonists [28, 29] provides powerful tools to determine the 
role of these receptors in mediating some of physiological 
and pharmacological effects in the myenteric neurones . 
 Given the relationship between CB1Rs/Opioid 
Withdrawal/Ach system, in the present paper we have 
designed new CB1Rs agonists named A-F [30, 31] and 
evaluated their role in mediating morphine withdrawal in 
GPI. Also, a comparative study was performed by using the 
CB1Rs synthetic cannabinoid WIN 55,212-2 and CP 55,940.  
MATERIALS AND METHODS 
Morphine Withdrawal on Guinea-Pig Ileum  
  Male Charles River guinea-pigs (180-200 g) were used 
for all the experiments. Animal Care and use followed the Morphine Dependence and CB1 Receptors  The Open Biochemistry Journal, 2009, Volume 3    79 
directions of the Council of the European Communities 
(1986). The animals were housed in colony cage (4 guinea-
pig each) under conditions of standard light (light on from 
7.00 a.m. to 7.00 p.m.), temperature (22+1°C) and room 
humidity (60%+10%) conditions for at least 1 week before 
the experimental sessions. Food and water were available ad 
libitum. 
  The experimental procedure was that described 
previously [32]. The ilea were allowed to equilibrate for 40-
60 min without washing and the response to acetylcholine 
(Ach) was determined for three times (10
-6 M )  s o  t h a t  
response could be expressed as percentage of Ach 
maximum. A reproducible acute opiate dependence was 
obtained performing the following experimental procedure. 
A typical tracing of contracture responses of the ileum to 
repeated challenges with opiate and naloxone is shown in 
Fig. (1).  
  After three similar Ach responses, the preparation was 
electrically stimulated for 10-20 min, (0.5 msec pulse 
delivered transmurally, at a frequency of 10 sec at 
supramaximal voltage, 25V). Before the addition of the 
morphine to the bath, the electrical stimulation was switched 
off. Under these conditions, the first contact with the opioid 
agonist followed after a 4 min exposure by naloxone induced 
a strong contraction (about 80% of the Ach maximum).  
  However, after washout, another Ach response was 
performed (to verify whether the ileum responsiveness was 
modified after withdrawal contracture) (Fig. 1A) and, after 
30 min resting period under stimulation, a further 4 min 
exposure of the ileum (without electrical stimulation) to the 
opiate and naloxone elicited reproducible response.  
  Following washout, Ach response (Fig. 1B) and another 
30 min resting period under stimulation, the ileum responded 
again to the morphine and naloxone with the same intensity 
(Fig. 1C). In our experiments, to avoid a possible tolerance 
for repeated morphine injection, each preparation was 
submitted only to three challenges with morphine and 
naloxone. Naloxone per se did not produce effects on 
“naive” preparations or those washed after opiate contact. 
Experimental Procedure 
  The administration of CB1Rs agonists WIN 55,212-2, CP 
55,940 and A-F was performed according to the following 
schedule: 
a)  three Ach response 
b)  electrical stimulation (10-20 min) 
c)  morphine injection (10
-5 M) in absence of electrical 
stimulation (4 min) and the addition of naloxone   
(10
-5  M) with subsequent contraction (1° opioid 
withdrawal) 
d)  washout and Ach response 
e)  electrical stimulation (30 min) 
f)  CB1Rs agonists WIN 55,212-2, CP 55,940 or A-F 
(1x10
-8-5x10
-8-1x10
-7 M) without electrical 
stimulation injected 10 min before morphine followed 
by naloxone (2° opioid withdrawal) 
g)  washout Ach response 
h)  electrical stimulation (30 min) 
i)  final control opiate withdrawal (3° opioid withdrawal) 
Drugs 
  Naloxone HCl and WIN 55,212-2 (R(+)-(2,3-dihydro-
5methyl-3-((morpholinyl)methyl)pirrolo-(1.2.3.-sw)-1.4-
benzoxazinyl)-(1-naphthalenyl)methanone)mesylate, GDP 
and GTPS were purchased from Sigma Chemical Co. (St. 
Louis, MO, USA); morphine HCl was from Carlo Erba 
(Milan, Italy), CP 55,940 was obtained from Tocris (Bristol, 
UK). Rat brains were purchased from Pelfreeze Rogers, AR. 
[
35S]GTPS was purchased from New England Nuclear 
Corp., Boston, MA. 
Parameter Evaluation  
  Four parameters were evaluated: 
1)  Naloxone contracture: the size of the contraction 
produced by the naloxone challenge was expressed as 
a fraction of the maximum contraction obtained with 
the subsequent addition of Ach in the same piece of 
tissue according to the method previously described 
[32]: 
Response to naloxone x100
= Tension ratio
Maximum response to Ach  
2)  Ach response before and after the treatment: 
reduction or increase of the Ach responses in the 
post-drug expressed as a percentage of Ach response 
in the pre-drug. 
3)  Electrically stimulation contraction before and after 
the treatment: reduction or increase of the electrically 
stimulation contraction in the post-drug was 
expressed as a percentage of the electrical stimulation 
in the pre-drug. 
4)  Naloxone contraction before and after treatment: 
reduction or increase of the naloxone contraction in 
the post-drug was expressed as a percentage of the 
naloxone contraction in the pre-drug. 
Statistical Analysis  
  Results were tested for statistical significance using the 
Student's t-test for paired data when results before and after 
treatments on the same preparation were compared. The 
ED50 were computed from the dose-response curve by the 
method of Litchfield and Wilcoxon [33]. 
Chemistry Pathway 
 The  CB1Rs  (A-F) were synthesized as described 
previously [30,31]. Table 1 shows the structures of the new 
CB1Rs agonists (A-F). 
Binding Assay 
1. [
35S]GTPS Binding Assay. Cerebellar Membrane 
Preparation 
  The procedure was adapted from the method of Dodd et 
al. [34] The stripped rat brains were slightly thawed, and 
using a spatula, the cerebellum was removed and discarded; 
the remaining tissue was homogenized in ice-cold 
homogenization buffer (0.32 M sucrose, 10 mM Tris, 5 mM 80    The Open Biochemistry Journal, 2009, Volume 3  Capasso and Gallo 
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Fig. (1). Typical tracing of opioid withdrawal on guinea-pig ileum. A. 3 similar acetylcholine response (A), electrical stimulation, injection of 
the opioid agonist (OA) followed after 4 min of contact period by naloxone (N) which induces contraction (1° opioid withdrawal). After 
washout (), it was performed another A response. 
B: After 30 min resting period under electrical stimulation, a further 4 min exposure of the ileum to the OA and N elicited reproducible 
response (2° opioid withdrawal). 
C: After another 30 min resting period under electrical stimulation, the ileum responded again to the OA and N with the same intensity (3° 
opioid withdrawal). 
 
Table 1. 
 
 
 
 
 
CB1 Analogues  R  n  R1 
CB1R-A   5-n-phenyl 5  CH2CH2OH 
CB1R-B   5-n-phenyl 5  c.C3H5 
CB1R-C   5-n-phenyl   10  CH2-c-C3H5 
CB1R-D   5-n-phenyl 10  CH2CH2OH 
CB1R-E   5-n-phenyl   7  CH2CH2OH 
CB1R-F   5-n-phenil 7  c.C3H5 
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EDTA, pH 7.4). The homogenate suspension was 
centrifuged at 3700g  for 10 min. The supernatant was 
decanted, and 12 mL was layered over 10 mL of 1.2 M 
sucrose. These tubes were centrifuged in a L7-65 
ultracentrifuge using a 50.2 Ti rotor at 4 ˚C for 29 min at 44 
000 rpm. The layer at the interface was then removed and 
subjected to a second sucrose spin over 0.8 M sucrose. The 
pellet was resuspended in TME buffer (25 mM Tris base, 5 
mM MgCl2, 1 mM EDTA, pH 7.4), aliquoted, and stored at -
70 ˚C. Protein was determined using the method of Markwell 
et al. [35]. 
2. [
35S]GTPS Binding Assay (Table 2) 
  Our assay was based on a method by Selley et al. [36] 
and was adjusted for a 96-well plate analysis. Briefly, the rat 
membrane preparation (40-50 g of protein) was incubated 
for 1 h at 30 ˚C in assay buffer (10 mM Tris, 100 mM NaCl, 
5 mM MgCl2, 0.1% BSA) with 50 L of 50 M GDP, 50 L 
of 0.05 nM [
35S]GTPS, or 100 L of either; 10 M GTPS 
was used to measure the nonspecific binding, a series of 
different concentrations of the analogues being tested, or 
buffer alone as a control to obtain the baseline of GTPS 
stimulation. The reaction was terminated by rapid filtration 
through Whatman GF/B filters, with ice-cold wash buffer 
containing 0.5% bovine serum albumin using the Packard 
Filtermate. Bound radioactivity was measured on the 
Packard Top-Count microplate scintillation counter.  
Table 2.  EC50 and Emax Values of Anandamide Analogues for 
Stimulating [
35S]GTPS Binding in Rat Microsomal 
Membranes
a 
CB1 Analogues  EC50 (M)  Emax (%)  
A   0.48 ± 0.03  112 ± 4.8  
B   0.22 ± 0.07  121 ± 1.5  
C   0.34 ± 0.08  133 ± 3.5  
D  0.52 ± 0.05  108 ± 2.7  
E  0.42 ± 0.03  103 ± 1.9  
F  0.27 ± 0.04  127 ± 4.5  
WIN 55,212-2   0.18 ± 0.09  144 ± 6.5  
CP-55,940   0.10 ± 0.05   135 ± 9.0 
a[
35S]GTP-S binding assay was conducted using eight concentrations of each analogue 
being tested and two experiments run with four duplicates of each point. 
 
RESULTS  
Effect of WIN 55,212-2, CP 55,940 or CB1R Agonists (A-
F) on Morphine Withdrawal 
  Both WIN 55,212-2 and CP 55,940 (CB1Rs synthetic 
cannabinoid) at 1x10
-8-5x10
-8-1x10
-7 M were able to 
respectively prevent or reverse the naloxone-induced 
contraction in GPI exposed to morphine (Table 3).  
  Also, six new CB1Rs agonists (A-F) (1x10
-8-5x10
-8-
1x10
-7 M) were able to reduce morphine withdrawal (Table 
3).  
Table 3.  ED50 and 95% C.L. Values of CB1Rs Agonist WIN 
55,212-2, CP 55,940 or A-F (1x10
-8-5x10
-8-1x10
-7 M) 
on Morphine Withdrawal. Each CB1Rs Agonist was 
Administered 10 min Before (A) or After (B) 
Morphine 
Compounds Morphine  Withdrawal 
(A) 
Morphine Withdrawal 
(B) 
WIN 55,212-2 2.1x10
-8 M  
(1.5x10
-9-2.4x10
-7) 
3.1x10
-8 M 
(5.5x10
-9-3.1x10
-7). 
CP 55,940 2,5x10
-8 M 
(3.5x10
-9-4.3x10
-7) 
3.5x10
-8 M  
(2.7x10
-9-4.3x10
-7). 
CB1R-A  3.5x10
-8 M  
(2.5x10
-9-1.9x10
-8) 
3.7x10
-8 M  
(4.5x10
-9-2.3x10
-7) 
CB1R-B  2.7x10
-8 M  
(3.4x10
-9-1.7x10
-8) 
2.9x10
-8 M  
(3.5x10
-9-1.7x10
-7) 
CB1R-C  3.1x10
-8 M  
(2.9x10
-9-4.1x10
-8) 
3.5x10
-8 M  
(2.5x10
-9-4.3x10
-7) 
CB1R-D  2.9x10
-8 M  
(1.3x10
-9-3.3x10
-8) 
2.2x10
-8 M  
(1.5x10
-9-3.3x10
-7) 
CB1R-E  2.4x10
-8 M  
(3.3x10
-9-1.9x10
-8) 
3.2x10
-8 M  
(4.5x10
-9-2.3x10
-7) 
CB1R-F  2.5x10
-8 M  
(3.3x10
-9-1.6x10
-8) 
3.6x10
-8 M  
(4.5x10
-9-2.3x10
-7) 
 
  Electrical stimulation was also reduced by the above CB1 
receptor agonists (Table 4), the final morphine withdrawal 
was still reduced (Table 4), whereas the Ach response was 
not modified (Data not shown). 
DISCUSSION 
  While there are several data in literature on the effects 
exerted by cannabinoids on several effects induced by 
opioids [37-40], this is the first paper which evaluates the 
role of CB1Rs agonists in mediating morphine withdrawal in 
vitro. Furthermore, a comparative study was also performed 
by using both the well known CB1Rs agonists WIN 55,212-
2 and CP 55,940 (CB1 synthetic cannabinoid) and six new 82    The Open Biochemistry Journal, 2009, Volume 3  Capasso and Gallo 
CB1Rs agonists (A-F). The results of the present study 
indicate that both the synthetic cannabinoid WIN 55,212-2 
or CP 55,940 as well as the six new CB1Rs agonists (A-F) 
were able to produce significant reduction on morphine 
withdrawal in vitro thus confirming the important functional 
interaction between the cannabinoid and opioid system.  
  However it is of interest to note that CB1Rs agonists (A-
F) compared to the synthetic cannabinoid WIN 55,212-2 and 
CP 55,940 showed a very similar activity in inhibiting 
morphine withdrawal confirming that CB1Rs agonists (A-F) 
show a CB1 receptor affinity very similar to WIN 55,212-2 
and CP 55,940 as shown in Table 2.  
  The discussion on the possible mechanism by which 
CB1Rs agonists causes a reducing effect on morphine 
withdrawal is open and several possibilities may be 
considered.  
  Ach system has been widely implicated in many of the 
pharmacological effects of opioids. Manipulation that alter 
the activity of Ach in the central nervous system frequently 
modify the effects of morphine and other opioid drugs [41-
44]. 
  Several authors have demonstrated that Ach agonists and 
antagonists are able to influence opiate withdrawal in vitro, 
suggesting an important functional interaction between the 
Ach system and opioid withdrawal [19-22]. Cholinergic 
agonist exacerbate opioid withdrawal; whereas, muscarinic 
and nicotinic blockers attenuate some aspects of the 
syndrome [19-22]. Furthermore, a large proportion of the 
contraction due to opioid withdrawal is caused by Ach 
release since it can be blocked by atropine or hyoscine [19-
22]. Also, it has been demonstrated that also selective 
muscarinic receptors antagonists are able to influence opioid 
withdrawal in vitro [45].  
  Several pharmacological evidences suggest that CB1Rs 
are present in the myenteric neurones and the effects on 
gastrointestinal motility depend on the activation of CB1Rs 
which induce a reduction of Ach release [23-27]. Therefore, 
the ability of CB1Rs agonists to reduce morphine withdrawal 
may be related to their ability to block the release of Ach at 
presynaptic level [23-27] and confirming the role played by 
Ach in the expression of opiate withdrawal [19-22].  
  Furthermore, in our experimental conditions, the ability 
of CB1Rs agonists to reduce electrical stimulation after 
washout without altering the Ach response at postsynaptic 
level confirm a direct action on presynaptic Ach receptors 
[23-27]. 
  Therefore, our data confirm and extend previous data 
[19-22] indicating a significative role of the cannabinoid 
system in the development of morphine withdrawal 
indicating that CB1Rs play an important role in the control 
of morphine withdrawal probably through Ach system [23, 
27, 46]. 
However, another possibility should be considered. 
  The effects of CB1Rs on morphine withdrawal may be 
also related to their ability to block the release of adrenaline 
or dopamine by pre-synaptic receptors. Recently, it has been 
demonstrated that catecolaminergic system is involved in the 
control of the expression of opioid acute dependence in GPI 
[32, 47]. Several studies indicate that CB1Rs are able to 
block the release of dopamine and noradrenaline at 
presynaptic level of guinea pig ileum electrically stimulated 
[48]. Therefore, we cannot exclude the possibility that 
CB1Rs reduce morphine withdrawal also by blocking the 
release of catecolamines by the presynaptic neurons. 
  Regarding the comparative study performed between the 
well known CB1Rs WIN 55,212-2 and CP 55,940 (CB1 
synthetic cannabinoid) and the six new CB1Rs agonists (A-
F). our data show a good correlation between the binding 
activity and biological activity,. Therefore, our results 
indicate that the aromatic structure, the length of aliphatic 
chain and the chain of 5-10 carbon atoms assure the affinity 
of compounds to CB1Rs. 
  Finally, the possible implications of this finding in the 
context of novel therapeutic aspect may be considered 
suggesting that CB1Rs activation or inhibition may result 
benefical as additional therapeutic strategy during opioid 
withdrawal. 
Table  4.  The Effect of CB1Rs Agonist WIN 55,212-2, CP 
55,940 or A-F [(1) 1x10
-7-(2) 5x10
-8- (3) 1x10
-8 M] on 
Electrical Stimulation and Final Opioid Withdrawal 
Compounds Electrical   
Stimulation 
Final Morphine 
Withdrawal 
WIN 55,212-2   75.6+3.9** 1 
 46.8+2.7** 2 
 35.4+1.6** 3 
 62.5+5.3** 1 
 39.7+3.1* 2 
 22.4+2.3 3 
CP 55,940   82.3+4.8** 1 
 56.3+2.4** 2 
 37.3+2.7 3 
 57.3+2.5** 1 
 44.8+4.9* 2 
 35.3+2.4 3 
CB1R-A   72.8+2.5** 1 
 49.7+2.9** 2 
 33.2+3.6 3 
 72.3+3.7** 1 
 57.2+3.6** 2 
 41.5+3.2* 3 
CB1R-B   77.5+4.2** 1 
 59.3+3.6** 2 
 23.7+2.5 3 
 69.5+4.6** 1 
 42.5+2.3** 2 
 28.7+3.9 3 
CB1R-C   69.3+5.8** 1 
 48.4+3.2** 2 
 32.3+2.1 3 
 68.7+5.1** 1 
 44.3+2.1** 2 
 20.7.6+1.9 3 
CB1R-D   73.1+6.7** 1 
 55.1+3.2** 2 
 38.3+2.5 3 
 70.2+6.2** 1 
 48.2+3.3** 2 
 27.3+3.1 3 
CB1R-E   67.3+6.1** 1 
 46.9+2.9** 2 
 36.2+6.5 3 
 73.4+4.3** 1 
62.5+2.5** 2 
 44.3+5.8 3 
CB1R-F   80.1+5.7** 1 
 63.9+3.5** 2 
 49.2+3.9** 3 
79.2+6.1** 1 
59.3+3.1** 2 
 46.2+2.2** 3 
Results are expressed as % of inhibition (mean+s.e.m.); *P<0.05; **P<0.01. All data 
were compared to the pre-drug. Morphine Dependence and CB1 Receptors  The Open Biochemistry Journal, 2009, Volume 3    83 
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